The global companion diagnostics (CDx) development market size was valued at USD 845.99 million in 2024 and is anticipated to register a CAGR of 7.6% from 2025 to 2034. This growth reflects the increasingly pivotal role of CDx assays, biomarker panels and co‑development strategies in enabling precision medicine and personalising therapeutic regimens. As drug manufacturers continue to align...